SEC Form 4 · accession 0001232524-17-000073
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul Treacy
Officer — SVP, Technical Operations
Period of report
Mar 6, 2017
Accepted (ET)
Mar 8, 2017 · 5:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2 | Mar 6, 2017 | S | 355 | $131.9745 | D | 18,108 | D | |
| Ordinary SharesF3 | Mar 6, 2017 | S | 529 | $131.9749 | D | 17,579 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
- F2Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $131.4935 to $131.9800. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F3Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $131.5330 to $131.9800. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.